Therefore, the clinical efficacy of CDK4/6 inhibitors in NSCLC depend on the development of predictive biomarkers and biologically rational combination therapy, which might include the addition of growth factor pathway inhibitors in patients with signal transduction pathway mutations or the addition of immune checkpoint inhibitors in patients with immunostimulatory tumor phenotypes. The gene discussed is CDK4; the disease is neoplasm.